Levicept
CompanyUnited Kingdom
Levicept develops one asset, in phase 2 (LEVI-04 in arthritis). Mostly protein or enzyme acting on NTF3; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 2
- 2
- Trials
- 1
- Signal
Pipeline
1Soluble neurotrophin receptor fusion protein that binds neurotrophin-3 to reduce pain signaling.
Phase 2, Protein or enzyme, NTF3, arthritis, joint diseases
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Signals2
- Similar companies6